Aptorum Group (APM) AI Stock Analysis

• Market Cap: $6.84M
• Dividend Yield: N/A
• Average Volume (3M): 113.32K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.46
• Revenue Growth: N/A
• EPS Growth: -1979.68%
• Country: US
• Employees: 1
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.06
• Shares Outstanding: 6,346,823
• 10 Day Avg. Volume: 164,850
• 30 Day Avg. Volume: 113,319
• PEG Ratio: -0.14
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -12.82
• Enterprise Value/Market Cap: 0.87
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -23.22
• Enterprise Value/Ebitda: -1.58
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 41 Neutral
• Price Target: $0.81 ▼(-24.11% Downside)
• Action: Reiterated Date: 02/03/26
• Date: Action: Reiterated 02/03/26

The score is driven primarily by weak financial performance, marked by zero recent revenue, ongoing losses, and negative cash flow. Technical indicators also point to a sustained downtrend (price below key moving averages and negative MACD), while valuation is constrained by a negative P/E and no dividend yield data.

Positive Factors

Modest leverage on balance sheet

Relatively low and improving leverage provides durable financial flexibility for a development-stage biotech. Lower debt service reduces near-term cash demands, enabling focus on R&D, partnerships, or M&A without immediate solvency pressure and supports strategic optionality over months.

Partnership/licensing-oriented business model

Agnostic go-to-market via licensing or selective commercialization suits a small clinical-stage biotech: it limits upfront commercial spend, leverages larger partners' distribution and regulatory capacity, and creates milestone/royalty upside that can sustainably fund R&D if candidates progress.

Strategic merger and diagnostics validation activity

Advancing the DiamiR merger and ongoing validation collaborations (e.g., APOE testing) represent structural moves to add CLIA/CAP-certified diagnostics capability and scale. A successful integration could create durable revenue channels and accelerate commercialization of diagnostic services.

Negative Factors

Zero recent revenue with persistent operating losses

Eliminating product revenue while continuing to report losses is a long-term concern: without commercialized products or material licensing cash-ins, the company must rely on financing. That structural revenue shortfall increases execution and funding risk over the next several quarters.

Negative operating cash flow and ongoing burn

Consistent negative operating and free cash flow demonstrates the business cannot self-fund development. Persistent cash burn forces reliance on capital markets or partners, which can dilute shareholders, constrain program timelines, and limit sustained investment in clinical development.

Shrinking assets and equity over time

Material declines in assets and shareholders' equity reflect prolonged value erosion from operating losses. Reduced balance sheet reserves constrain the company's ability to fund trials, secure partnerships, or withstand setbacks, increasing structural financing pressure in the medium term.

Aptorum Group Business Overview & Revenue Model

Company Description

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom.

How the Company Makes Money

Aptorum Group generates revenue primarily through the development and commercialization of pharmaceutical products. The company engages in the research and development of novel therapeutics, which, upon reaching successful clinical trial phases and receiving regulatory approvals, are either marketed directly or licensed to larger pharmaceutical companies that handle distribution. Licensing agreements and partnerships with other biotech firms and research institutions are significant contributors to its revenue, allowing Aptorum Group to leverage external expertise and resources to enhance its drug development pipeline. Additionally, Aptorum explores revenue generation through its healthcare consumer products segment, which involves the sale of non-pharmaceutical products that align with its core focus on health and wellness.

Aptorum Group Financial Statement Overview

Summary

Financial performance is weak: revenue declined to $0 in 2024 annual with negative gross profit and persistent net losses. Cash flow remains negative (ongoing burn), though leverage is modest and improved, which provides some flexibility but does not offset shrinking assets/equity and funding risk.

Income Statement

Operating performance remains weak and volatile. Revenue fell from $1.30M (2022) to $0.43M (2023) and then to $0 (2024 annual), while gross profit was negative in 2024 and margins have generally been thin/negative. Losses are persistent (net income: -$9.8M in 2022, -$2.8M in 2023, -$4.3M in 2024 annual), indicating an ongoing inability to cover operating costs. A notable outlier is 2020, which shows positive net income, but the company has not sustained profitability since.

Balance Sheet

The balance sheet is a relative bright spot: leverage is modest with debt-to-equity at ~0.16 in 2024 annual (improved vs. ~0.44 in 2022), suggesting manageable debt levels. However, equity and assets have trended down over time (equity: ~$41.8M in 2020 to ~$21.1M in 2024 annual; assets: ~$44.2M to ~$16.1M), consistent with ongoing losses and cash use. Returns to shareholders remain negative in recent years, reflecting continued value erosion despite lower leverage.

Cash Flow

Cash generation is weak, with operating cash flow and free cash flow negative every year shown (2024 annual operating cash flow: -$1.2M vs. -$7.7M in 2023, an improvement but still a burn). Free cash flow deterioration is significant in 2024 annual (free cash flow growth: -57.7%), and cash flow does not cover earnings in a supportive way because both remain negative. Overall, the business appears reliant on financing and/or balance sheet resources rather than internally generated cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	431.38K	1.30M	1.54M	911.51K
Gross Profit	-255.00K	10.57K	80.06K	81.85K	-104.00K
EBITDA	-3.76M	-9.48M	-10.32M	-25.83M	6.50M
Net Income	-4.27M	-2.83M	-9.80M	-25.05M	7.07M
Balance Sheet
Total Assets	16.13M	20.64M	20.87M	21.91M	44.23M
Cash, Cash Equivalents and Short-Term Investments	874.24K	2.01M	1.99M	8.50M	31.88M
Total Debt	3.35M	3.49M	6.85M	217.17K	3.32M
Total Liabilities	4.35M	5.26M	13.03M	4.40M	6.08M
Stockholders Equity	21.13M	24.85M	15.71M	23.61M	41.83M
Cash Flow
Free Cash Flow	-1.19M	-7.73M	-12.51M	-14.79M	-16.09M
Operating Cash Flow	-1.19M	-7.72M	-12.32M	-14.65M	-15.93M
Investing Cash Flow	58.62K	624.77K	2.44M	16.51M	1.84M
Financing Cash Flow	1.43K	4.09M	6.63M	2.78M	12.42M

Aptorum Group Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.07
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APM, the sentiment is Negative. The current price of 1.07 is above the 20-day moving average (MA) of 0.84, above the 50-day MA of 1.00, and below the 200-day MA of 1.34, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 40.73 is Neutral, neither overbought nor oversold. The STOCH value of 64.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APM.

Aptorum Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AEON	54 Neutral	$28.34M	0.24	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IMNN	48 Neutral	$10.95M	-0.31	-233.50%	―	―	57.97%
DWTX	45 Neutral	$99.22M	-0.12	-97.54%	―	―	-295.27%
APM	41 Neutral	$6.84M	-2.28	-9.02%	―	―	-1979.68%

Aptorum Group Corporate Events

Aptorum Updates Investors With Interim and Pro Forma Financials Ahead of DiamiR Merger

On January 21, 2026, Aptorum Group Limited filed a Form 6-K providing investors with unaudited interim condensed consolidated financial statements for the nine months ended September 30, 2025, alongside DiamiR Biosciences Corp.’s unaudited financials for the six months ended November 30, 2025 and unaudited pro forma condensed combined financial statements. The disclosure is part of the company’s ongoing process to complete its previously announced July 14, 2025 merger with DiamiR, for which Aptorum will create a Delaware merger subsidiary that will be combined into DiamiR, leaving DiamiR as a wholly owned subsidiary; by updating and incorporating both companies’ financials into existing U.S. registration statements, Aptorum is advancing the regulatory and shareholder information requirements needed for closing the transaction and giving stakeholders an early view of the combined entity’s prospective financial profile.

The most recent analyst rating on (APM) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on Aptorum Group stock, see the APM Stock Forecast page.